Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukaemia with a Consideration of Socio-economic Characteristics: A Retrospective Study from a Single Centre
To compare the efficacy and safety of generic and branded imatinib in adults with newly diagnosed chronic myeloid leukaemia in the chronic phase (CML-CP), we retrospectively reviewed data from patients CML-CP receiving generic or branded imatinib.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Xuelin Dou, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang, Qian Jiang Tags: Original Study Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Hematology | Leukemia | Lymphoma | Myeloma | Study